{"entity":{"id":"nct04914598","kind":"trial","name":"A Phase Ⅲ Clinical Study of Combined Cisplatin Versus Placebo Combined With Intracavitary Cisplatin Injection in the Treatment of Malignant Pleural Effusions","aka":[],"tldr":"A phase 3 trial of Cisplatin in advanced solid tumours, run by Jiangsu Simcere Pharmaceutical Co., Ltd., active and no longer recruiting.","summary":"A Phase Ⅲ Clinical Study of Combined Cisplatin Versus Placebo Combined With Intracavitary Cisplatin Injection in the Treatment of Malignant Pleural Effusions is a phase 3 interventional study registered as NCT04914598 by Jiangsu Simcere Pharmaceutical Co., Ltd., with 290 participants enrolled, started 2021-07-28 and due to reach its primary completion in 2025-02-10. Interventions recorded: ENDOSTAR，cisplatin and Placebo , cisplatin.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04914598","url":"https://clinicaltrials.gov/study/NCT04914598"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["cisplatin"],"companies":["simcere"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04914598","phase":"3","setting":"A Randomized, Controlled, Double-blind, Multi-center Phase Ⅲ Registration Clinical Study of Combined Cisplatin Versus Placebo Combined With Intracavitary Cisplatin Injection in the Treatment of Malignant Pleural Effusions","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","enrolled":290,"outcomes":[]},"route":"/trials/nct04914598/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"}],"company":[{"id":"simcere","kind":"company","name":"Simcere Pharmaceutical","route":"/companies/simcere/"}]}}